Intercytex announces introduction of Vavelta at FACE

Stem cell; cell based hair therapy
21

» what is the difference between autologous and allogenic.

in the case of a procedure dealing with cells, roughly speaking :
autologous -> use of your own, auto, cells.
allogenic -> use of ‘others’, allo, cells

Autologous: In blood transfusion and transplantation, a situation in which the donor and recipient are the same person.

Being genetically different although belonging to or obtained from the same species: allogeneic tissue grafts.

22

As a whole this is good news as it shows that Intercytex r the real deal and serious about commercialising all of the products ASAP

we can c with vavalta that the commercial lauch is taking place between phase IIa - phase IIb. They’re not only skipping phase III but they’re skipping a massive chunk of phase II trials.

Technically TRC and vavelta r at the same stage with regards to clinical trials. It’s just that vavalta has been giving the go ahead by the MHRA to be launched sooner but i bet u that there r some countries who will happily accomodate TRC b4 phase III commences.

“Although not required to undertake clinical trials by law, Intercytex believes that it is the appropriate and responsible course to comprehensively evaluate its product. This will ensure patient and clinician confidence and is in anticipation of new legislation relating to products such as VAVELTA™.” source - Intercytex

23

» As a whole this is good news as it shows that Intercytex r the real deal
» and serious about commercialising all of the products ASAP
»
» we can c with vavalta that the commercial lauch is taking place between
» phase IIa - phase IIb. They’re not only skipping phase III but they’re
» skipping a massive chunk of phase II trials.
»
» Technically TRC and vavelta r at the same stage with regards to clinical
» trials. It’s just that vavalta has been giving the go ahead by the MHRA to
» be launched sooner but i bet u that there r some countries who will happily
» accomodate TRC b4 phase III commences.
»
» “Although not required to undertake clinical trials by law, Intercytex
» believes that it is the appropriate and responsible course to
» comprehensively evaluate its product. This will ensure patient and
» clinician confidence and is in anticipation of new legislation relating to
» products such as VAVELTA™.” source - Intercytex.

As it seems, TRC phase II trials will continue until mid 2008. Despite the fact that the will release preliminary data on the end of September 2007, i believe they have a lot of things to test.

But lets us consider to be lucky and assume that Intercytex found the optimal DP 's administration dosage by the first cohorts…:ok:

24

» As it seems, TRC phase II trials will continue until mid 2008.

Mid 2008? where did you read this?

25

» » As it seems, TRC phase II trials will continue until mid 2008.
»
» Mid 2008? where did you read this?

Intercytex has announced that phase II trials will end on 2008. Add some months (they always miss they’re deadlines) and there you go!